Clinical Staging, Histopathological Features and Treatment Outcomes in Malignant Melanoma: A 10-Year Retrospective Single-Center Study
| dc.authorscopusid | 60108079400 | |
| dc.authorscopusid | 6507569757 | |
| dc.contributor.author | Turkoglu, Z. | |
| dc.contributor.author | Esen, R. | |
| dc.date.accessioned | 2025-10-30T15:28:25Z | |
| dc.date.available | 2025-10-30T15:28:25Z | |
| dc.date.issued | 2025 | |
| dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
| dc.department-temp | [Turkoglu] Zarife, Department of Internal Medicine, Van Yüzüncü Yıl Üniversitesi, Van, Turkey; [Esen] Ramazan, Division of Medical Oncology, Van Yüzüncü Yıl Üniversitesi, Van, Turkey | en_US |
| dc.description.abstract | Objectives: We aimed to retrospectively evaluate the clinical stage at diagnosis, histopathological features and treatment outcomes of adult patients with malignant melanoma over a 10-year period at Van YüzüncüYıl University Hospital. Materials and Methods: We reviewed 95 adult patients diagnosed between January 2010 and December 2019. Collected data included demographics, melanoma subtypes, tumor location, AJCC stage, treatment approaches and survival outcomes. Results: The cohort consisted of 52.6% males and 47.4% females, with a mean age of 56.9±16.4 years. Cutaneous melanoma was the most common subtype (81.1%), with nodular melanoma as the predominant histological type. Lesion location significantly affected survival (*p*<0.05). Stage IV was the most frequent at diagnosis (43.2%). Interferon and chemotherapy were common adjuvant therapies. All ocular melanoma cases underwent surgical enucleation. The median follow-up was 24.4 months. Median overall survival was 11.3 months; the 5-year survival rate was 63.6%. Conclusion: Our findings emphasize the prognostic impact of histological subtype, tumor site and disease stage at diagnosis. Expanded access to novel therapies may improve outcomes in this patient population. © 2025 Elsevier B.V., All rights reserved. | en_US |
| dc.identifier.doi | 10.5530/jbuon.20250033 | |
| dc.identifier.endpage | 15 | en_US |
| dc.identifier.issn | 1107-0625 | |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.scopus | 2-s2.0-105016592747 | |
| dc.identifier.scopusquality | N/A | |
| dc.identifier.startpage | 7 | en_US |
| dc.identifier.uri | https://doi.org/10.5530/jbuon.20250033 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14720/28808 | |
| dc.identifier.volume | 28 | en_US |
| dc.identifier.wosquality | N/A | |
| dc.language.iso | en | en_US |
| dc.publisher | Zerbinis Publications | en_US |
| dc.relation.ispartof | Journal of B.U.ON. | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Clinical Staging | en_US |
| dc.subject | Histopathology | en_US |
| dc.subject | Malignant Melanoma | en_US |
| dc.subject | Survival | en_US |
| dc.subject | Treatment | en_US |
| dc.title | Clinical Staging, Histopathological Features and Treatment Outcomes in Malignant Melanoma: A 10-Year Retrospective Single-Center Study | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |